FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320482535> ?p ?o ?g. }

• W4320482535 endingPage "2735" @default.
• W4320482535 startingPage "2724" @default.
• W4320482535 abstract "Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (PFS) for nivolumab and relatlimab over nivolumab in previously untreated advanced melanoma.The phase I/IIa, open-label RELATIVITY-020 trial part D assessed efficacy and safety of nivolumab and relatlimab in advanced melanoma with progression during, or within 3 months of, 1 (D1) or ≥ 1 (D2) anti-PD-(L)1-containing regimens. Safety was a primary end point. Objective response rate (coprimary end point) and PFS by blinded independent central review (BICR) were assessed.Five hundred eighteen patients (D1 = 354; D2 = 164) received nivolumab and relatlimab. Among evaluable patients, the objective response rate by BICR was 12.0% (95% CI, 8.8 to 15.8) in D1 (n = 351) and 9.2% (95% CI, 5.2 to 14.7) in D2 (n = 163). Responses appeared to be enriched among patients with tumors expressing programmed death ligand 1 or lymphocyte activation gene 3; however, responses were observed regardless of programmed death ligand 1 and lymphocyte activation gene 3 expression (1%). The median duration of response was not reached (95% CI, 12.9 to not reached) in D1 and 12.8 months (95% CI, 6.9 to 12.9) in D2. The median PFS by BICR was 2.1 months (95% CI, 1.9 to 3.5) in D1 and 3.2 months (95% CI, 1.9 to 3.6) in D2; the 6-month PFS rate was 29.1% (95% CI, 24.2 to 34.1) and 27.7% (95% CI, 20.5 to 35.4), respectively. The grade 3-4 treatment-related adverse event incidence was 15.0% in D1 and 12.8% in D2. One case of grade 3 myocarditis and no treatment-related deaths occurred across part D.Nivolumab and relatlimab had a manageable safety profile and demonstrated durable clinical activity in a proportion of patients with heavily pretreated advanced melanoma with prior progression on anti-PD-(L)1-containing regimens.[Media: see text]." @default.
• W4320482535 created "2023-02-14" @default.
• W4320482535 creator A5000768609 @default.
• W4320482535 creator A5001281569 @default.
• W4320482535 creator A5001893646 @default.
• W4320482535 creator A5002046745 @default.
• W4320482535 creator A5002644565 @default.
• W4320482535 creator A5005462156 @default.
• W4320482535 creator A5008736570 @default.
• W4320482535 creator A5011114578 @default.
• W4320482535 creator A5014494747 @default.
• W4320482535 creator A5022616203 @default.
• W4320482535 creator A5031591368 @default.
• W4320482535 creator A5032262791 @default.
• W4320482535 creator A5033755552 @default.
• W4320482535 creator A5034365278 @default.
• W4320482535 creator A5049455638 @default.
• W4320482535 creator A5054723003 @default.
• W4320482535 creator A5056360160 @default.
• W4320482535 creator A5064188023 @default.
• W4320482535 creator A5071577704 @default.
• W4320482535 creator A5073133195 @default.
• W4320482535 creator A5076054848 @default.
• W4320482535 creator A5089297467 @default.
• W4320482535 date "2023-05-20" @default.
• W4320482535 modified "2023-10-14" @default.
• W4320482535 title "Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial" @default.
• W4320482535 cites W2166662937 @default.
• W4320482535 cites W2572174216 @default.
• W4320482535 cites W2753432434 @default.
• W4320482535 cites W2757936530 @default.
• W4320482535 cites W2763833329 @default.
• W4320482535 cites W2763933536 @default.
• W4320482535 cites W2963476376 @default.
• W4320482535 cites W3029460267 @default.
• W4320482535 cites W3043703771 @default.
• W4320482535 cites W3162968491 @default.
• W4320482535 cites W3163284774 @default.
• W4320482535 cites W3166578944 @default.
• W4320482535 cites W3195875128 @default.
• W4320482535 cites W3210866519 @default.
• W4320482535 cites W4210844982 @default.
• W4320482535 cites W4225394054 @default.
• W4320482535 doi "https://doi.org/10.1200/jco.22.02072" @default.
• W4320482535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36780608" @default.
• W4320482535 hasPublicationYear "2023" @default.
• W4320482535 type Work @default.
• W4320482535 citedByCount "12" @default.
• W4320482535 countsByYear W43204825352023 @default.
• W4320482535 crossrefType "journal-article" @default.
• W4320482535 hasAuthorship W4320482535A5000768609 @default.
• W4320482535 hasAuthorship W4320482535A5001281569 @default.
• W4320482535 hasAuthorship W4320482535A5001893646 @default.
• W4320482535 hasAuthorship W4320482535A5002046745 @default.
• W4320482535 hasAuthorship W4320482535A5002644565 @default.
• W4320482535 hasAuthorship W4320482535A5005462156 @default.
• W4320482535 hasAuthorship W4320482535A5008736570 @default.
• W4320482535 hasAuthorship W4320482535A5011114578 @default.
• W4320482535 hasAuthorship W4320482535A5014494747 @default.
• W4320482535 hasAuthorship W4320482535A5022616203 @default.
• W4320482535 hasAuthorship W4320482535A5031591368 @default.
• W4320482535 hasAuthorship W4320482535A5032262791 @default.
• W4320482535 hasAuthorship W4320482535A5033755552 @default.
• W4320482535 hasAuthorship W4320482535A5034365278 @default.
• W4320482535 hasAuthorship W4320482535A5049455638 @default.
• W4320482535 hasAuthorship W4320482535A5054723003 @default.
• W4320482535 hasAuthorship W4320482535A5056360160 @default.
• W4320482535 hasAuthorship W4320482535A5064188023 @default.
• W4320482535 hasAuthorship W4320482535A5071577704 @default.
• W4320482535 hasAuthorship W4320482535A5073133195 @default.
• W4320482535 hasAuthorship W4320482535A5076054848 @default.
• W4320482535 hasAuthorship W4320482535A5089297467 @default.
• W4320482535 hasBestOaLocation W43204825352 @default.
• W4320482535 hasConcept C121608353 @default.
• W4320482535 hasConcept C126322002 @default.
• W4320482535 hasConcept C143998085 @default.
• W4320482535 hasConcept C203092338 @default.
• W4320482535 hasConcept C2777658100 @default.
• W4320482535 hasConcept C2777701055 @default.
• W4320482535 hasConcept C2780030458 @default.
• W4320482535 hasConcept C502942594 @default.
• W4320482535 hasConcept C535046627 @default.
• W4320482535 hasConcept C71924100 @default.
• W4320482535 hasConceptScore W4320482535C121608353 @default.
• W4320482535 hasConceptScore W4320482535C126322002 @default.
• W4320482535 hasConceptScore W4320482535C143998085 @default.
• W4320482535 hasConceptScore W4320482535C203092338 @default.
• W4320482535 hasConceptScore W4320482535C2777658100 @default.
• W4320482535 hasConceptScore W4320482535C2777701055 @default.
• W4320482535 hasConceptScore W4320482535C2780030458 @default.
• W4320482535 hasConceptScore W4320482535C502942594 @default.
• W4320482535 hasConceptScore W4320482535C535046627 @default.
• W4320482535 hasConceptScore W4320482535C71924100 @default.
• W4320482535 hasIssue "15" @default.
• W4320482535 hasLocation W43204825351 @default.
• W4320482535 hasLocation W43204825352 @default.
• W4320482535 hasLocation W43204825353 @default.
• W4320482535 hasLocation W43204825354 @default.

• next